| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 328.69 | 0.6% | 35.9% |
| Total Income | 328.69 | 0.6% | 35.9% |
| Expenditure | 387.96 | 4.2% | 21.7% |
| PBT | -1.75 | 100.5% | 101.1% |
| Net Profit | -4.89 | 101.5% | 102.5% |
| OPM | 4.04% | 95.95pp | 18.48pp |
| NPM | -1.49% | 101.49pp | 39.86pp |
| EPS | -0.05 | 101.6% | 102.5% |
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results
06 Aug 2026 · 6 Aug, 1:45 am
Summary
Sarepta Therapeutics announced its financial results for the second quarter of 2026, reporting total net product revenues of $328.7 million. Total revenues for the quarter were $401.3 million, a decrease compared to the prior year, primarily attributed to lower ELEVIDYS sales volume and a decrease in collaboration revenues. The company achieved operating profitability with GAAP operating income of $13.3 million and non-GAAP operating income of $86.5 million. Sarepta also narrowed its full-year 2026 revenue guidance to $1.2-$1.3 billion and maintained a strong financial position with approximately $945.0 million in cash.
Key Highlights
- 1
Sarepta Therapeutics reported total net product revenues of $328.7 million for the second quarter of 2026.
- 2
The company achieved both GAAP and non-GAAP operating income of $13.3 million and $86.5 million, respectively, for the second quarter of 2026.
- 3
Total revenues for the three months ended June 30, 2026, were $401.3 million, a decrease from $611.1 million in the same period of 2025.
- 4
For the six months ended June 30, 2026, total revenues were $1,132.1 million, a decrease from $1,355.9 million in the same period of 2025.
- 5
The company narrowed its FY 2026 total net product revenue guidance to $1.2-$1.3 billion.
- 6
Sarepta ended the quarter with approximately $945.0 million of cash, cash equivalents, restricted cash and investments.
Management Comments
Michael Severino
MD
As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients, and the significant opportunities ahead. Our second quarter results, including $328.7 million in total net product revenue and both GAAP and non-GAAP operating profitability, reflect the strength and resilience of our business. With important data readouts expected in DM1 and FSHD, continued progress across our broader pipeline, and a talented team dedicated to transforming the lives of patients with rare diseases, we have significant opportunities ahead and remain committed to delivering sustainable long-term value. Our priorities are clear: execute our commercial strategy, advance our promising siRNA pipeline, and continue allocating capital with discipline. With a strong balance sheet, an innovative pipeline, and an experienced leadership team, I believe Sarepta is well positioned to deliver on its long-term potential.
Informational and educational content only. Not investment advice.